journal
Journals Journal of Cardiovascular Phar...

Journal of Cardiovascular Pharmacology

https://read.qxmd.com/read/38422218/novel-therapeutic-insights-into-the-treatment-of-pericarditis-targeting-the-innate-immune-system
#21
JOURNAL ARTICLE
Alessandra Vecchié, Aldo Bonaventura, Michele Golino, Georgia Thomas, Antonio Abbate
Acute pericarditis is characterized by pericardial inflammation which can be treated with anti-inflammatory drugs. A considerable percentage of patients develops recurrent pericarditis with several relapses. In developed countries, the idiopathic form is the most frequent and has a high risk of recurrences. Two pathophysiological mechanisms have been described for idiopathic recurrent pericarditis, autoimmune and autoinflammatory. The autoimmune mechanism is more frequently encountered in patients with rheumatologic disorders, especially systemic lupus erythematosus...
February 29, 2024: Journal of Cardiovascular Pharmacology
https://read.qxmd.com/read/38422186/transcriptome-analysis-reveals-enhancement-of-cardiogenesis-related-signaling-pathways-by-s-nitroso-n-pivaloyl-d-penicillamine-snpip-implications-for-improved-diastolic-function-and-cardiac-performance
#22
JOURNAL ARTICLE
Yasuhiro Takenaka, Masataka Hirasaki, Hidemasa Bono, Shigeo Nakamura, Yoshihiko Kakinuma
We previously reported a novel compound called S-nitroso-N-pivaloyl-D-penicillamine (SNPiP), which was screened from a group of nitric oxide (NO) donor compounds with a basic chemical structure of S-nitroso-N-acetylpenicillamine (SNAP), to activate the non-neuronal acetylcholine (NNA) system. SNPiP-treated mice exhibited improved cardiac output and enhanced diastolic function, without an increase in heart rate. The NNA-activating effects included increased resilience to ischemia, modulation of energy metabolism preference, and activation of angiogenesis...
February 29, 2024: Journal of Cardiovascular Pharmacology
https://read.qxmd.com/read/38421206/atherosclerotic-plaque-erosion-mechanisms-clinical-implications-and-potential-therapeutic-strategies-a-review
#23
JOURNAL ARTICLE
Sharon Bruoha, Mattia Galli, Pierre Sabouret, Chaim Yosefy, Louay Taha, Felice Gragnano, Michael P Savage, Mony Shuvy, Giuseppe Biondi-Zoccai, Michael Glikson, Elad Asher
Atherosclerosis is an insidious and progressive inflammatory disease characterized by the formation of lipid-laden plaques within the intima of arterial walls with potentially devastating consequences. While rupture of vulnerable plaques has been extensively studied, a distinct mechanism known as plaque erosion has gained recognition and attention in recent years. Plaque erosion, characterized by the loss of endothelial cell lining in the presence of intact fibrous cap contributes to a significant and growing proportion of acute coronary events...
February 29, 2024: Journal of Cardiovascular Pharmacology
https://read.qxmd.com/read/38417026/association-of-il-17-inhibitors-with-hypertension-in-patients-with-autoimmune-diseases-a-systematic-review-and-meta-analysis-on-randomized-controlled-trials
#24
JOURNAL ARTICLE
Kexin Jiang, Yuheng Jia, Li Chen, Fangyang Huang, Mao Chen
The influence of IL-17 inhibition on blood pressure in autoimmune disease patients remains inconclusive. Our objective is to examine the risk of hypertension in patients with autoimmune diseases undergoing IL-17 inhibition therapies via meta-analysis of randomized, placebo-controlled trials (RCTs). We obtained integrated data from PubMed, Embase, and ClinicalTrials.gov. Incident hypertension rates were calculated, and hazard ratios (HRs) with 95% confidence intervals (CIs) were analyzed, along with Ι^2 statistics to assess heterogeneity...
February 27, 2024: Journal of Cardiovascular Pharmacology
https://read.qxmd.com/read/38416879/oral-oncolytics-and-cardiovascular-risk-management-and-monitoring-erratum
#25
JOURNAL ARTICLE
White Rt
No abstract text is available yet for this article.
February 15, 2024: Journal of Cardiovascular Pharmacology
https://read.qxmd.com/read/38416872/protective-effect-of-cd137-deficiency-against-post-infarction-cardiac-fibrosis-and-adverse-cardiac-remodeling-via-erk1-2-signaling-pathways
#26
JOURNAL ARTICLE
Guangyao Zang, Yiliu Chen, Ge Guo, Aijun Wan, Bo Li, Zhongqun Wang
Myocardial fibrosis, a common complication of myocardial infarction (MI), is characterized by excessive collagen deposition and can result in impaired cardiac function. The specific role of CD137 in the development of post-MI myocardial fibrosis remains unclear. Thus, this study aimed to elucidate the effects of CD137 signaling using CD137 knockout mice and in vitro experiments. CD137 expression levels progressively increased in the heart following MI, particularly in myofibroblast, which play a key role in fibrosis...
February 12, 2024: Journal of Cardiovascular Pharmacology
https://read.qxmd.com/read/38335530/current-treatment-and-immunomodulation-strategies-in-acute-myocarditis
#27
JOURNAL ARTICLE
Emma Ferone, Amitai Segev, Erika Tempo, Piero Gentile, Ahmed Elsanhoury, Chiara Baggio, Jessica Artico, Prashan Bhatti, Paul Scott, Emanuele Bobbio, Marco Merlo, Pietro Ameri, Gianfranco Sinagra, Carsten Tschöpe, Daniel Bromage, Antonio Cannata
Myocarditis is an inflammatory disease of the myocardium characterized by a great heterogeneity of presentation and evolution. Treatment of myocarditis is often supportive and the evidence for immunosuppression is scarce and debated. Conventional treatment is based on clinical presentation, ranging from conservative to advanced mechanical assist devices. In this setting, immunosuppression and immunomodulation therapies are mostly reserved for patients presenting with major clinical syndromes. In this review, we will summarise the current evidence and strategies for conventional and immunosuppressive treatments for patients presenting with acute myocarditis...
February 9, 2024: Journal of Cardiovascular Pharmacology
https://read.qxmd.com/read/38335531/antithrombotic-stewardship-evaluation-of-platelet-reactivity-guided-cangrelor-dosing-using-the-verifynow%C3%A2-assay
#28
JOURNAL ARTICLE
Alexander Connery, Tania Ahuja, Alyson Katz, Serena Arnouk, Eric Zhu, John Papadopoulos, Sunil Rao, Cristian Merchan
Cangrelor may be used as a bridge when temporary interruption of dual antiplatelet therapy (DAPT) is necessary. However, the optimal dose and monitoring of cangrelor in patients remains unknown, especially in the setting of mechanical circulatory support (MCS). We conducted an observational, single-center, retrospective cohort study of patients that had PCI within 3 months and received cangrelor while admitted to any intensive care unit. The primary outcome was the incidence of any major adverse cardiovascular event (MACE)...
February 8, 2024: Journal of Cardiovascular Pharmacology
https://read.qxmd.com/read/38324028/assessment-of-the-effectiveness-of-ticagrelor-preloading-in-mitigating-periprocedural-myocardial-injury-among-non-st-elevation-myocardial-infarction-patients-opting-for-an-early-invasive-approach
#29
JOURNAL ARTICLE
Alfredo Caturano, Davide Nilo, Vincenzo Russo, Raffaele Galiero, Marcellino Monda, Raffaele Marfella, Ferdinando Carlo Sasso
No abstract text is available yet for this article.
February 5, 2024: Journal of Cardiovascular Pharmacology
https://read.qxmd.com/read/38323891/exploring-the-promise-and-challenges-of-artificial-intelligence-in-biomedical-research-and-clinical-practice
#30
JOURNAL ARTICLE
Raffaele Altara, Cameron J Basson, Giuseppe Biondi-Zoccai, George W Booz
Artificial intelligence (AI) is poised to revolutionize how science, and biomedical research in particular, are done. With AI, problem solving and complex tasks using massive data sets can be performed at a much higher rate and dimensionality level compared to humans. With the ability to handle huge data sets and self-learn, AI is already being exploited in drug design, drug repurposing, toxicology, and material identification. AI could also be used in both basic and clinical research in study design, defining outcomes, analyzing data, interpreting findings, and even identifying the most appropriate areas of investigation and funding sources...
February 5, 2024: Journal of Cardiovascular Pharmacology
https://read.qxmd.com/read/38323905/short-chain-acyl-coa-dehydrogenase-as-a-therapeutic-target-for-cardiac-fibrosis
#31
JOURNAL ARTICLE
Zhaohui Shu, Jingyun Feng, Lanting Liu, Yingqin Liao, Yuhong Cao, Zhenhua Zeng, Qiuju Huang, Zhonghong Li, Guifang Jin, Zhicheng Yang, Jieyu Xing, Sigui Zhou
Cardiac fibrosis is considered as unbalanced extracellular matrix (ECM) production and degradation, contributing to heart failure. Short-chain acyl-CoA dehydrogenase (SCAD) negatively regulates pathological cardiac hypertrophy. The purpose of this study was to investigate the possible role of SCAD in cardiac fibrosis. In-vivo experiments were performed on spontaneously hypertensive rats (SHR) and SCAD knockout mice. The cardiac tissues of hypertensive patients with cardiac fibrosis were used for measurement of SCAD expression...
February 2, 2024: Journal of Cardiovascular Pharmacology
https://read.qxmd.com/read/38578774/the-role-of-sglt2-inhibitors-on-heart-failure-outcomes-in-nondiabetic-patients-a-systematic-review-and-meta-analysis-of-randomized-controlled-trials-erratum
#32
JOURNAL ARTICLE
(no author information available yet)
No abstract text is available yet for this article.
April 1, 2024: Journal of Cardiovascular Pharmacology
https://read.qxmd.com/read/37989136/the-role-of-sglt2-inhibitors-on-heart-failure-outcomes-in-nondiabetic-patients-a-systematic-review-and-meta-analysis-of-randomized-controlled-trials
#33
JOURNAL ARTICLE
Sharath Kommu
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) improve cardiovascular outcomes in patients with heart failure (HF). However, studies examining their benefits exclusively in nondiabetic patients on various HF outcomes are limited. By conducting a MEDLINE and ClinicalTrials.gov search for randomized controlled trials, we identified 4 studies on SGLT2i with data on HF outcomes in nondiabetic patients and performed a meta-analysis. There were 10.638 nondiabetic patients, with 5316 patients in the SGLT2i group and 5322 in the placebo group included in this meta-analysis...
February 1, 2024: Journal of Cardiovascular Pharmacology
https://read.qxmd.com/read/38241693/effect-of-benidipine-alone-and-in-combination-with-bosentan-and-sildenafil-in-amelioration-of-pulmonary-arterial-hypertension-in-experimental-model-in-rats
#34
JOURNAL ARTICLE
Kalpana Kumari, Vishal Kumar Vishwakarma, Kuldeep Kumar, Asit Ranjan Mridha, Sudhir Kumar Arava, Sameer Dhingra, Nirmal Singh, Harlokesh Narayan Yadav
Pulmonary arterial hypertension (PAH) is a persistent condition affecting the pulmonary arteries' endothelium. Benidipine, a calcium channel blocker, possesses vasodilatory, anti-inflammatory activity, reduces oxidative stress, and inhibits the activity of TGF-β receptor 1 and α-SMA. The present study was designed to investigate the effect of benidipine alone and in combination with bosentan and sildenafil on monocrotaline (MCT)-induced pulmonary hypertension (PH) in a rat model. PAH was induced by single-dose administration of MCT in rats...
January 17, 2024: Journal of Cardiovascular Pharmacology
https://read.qxmd.com/read/38241694/impact-of-preloading-strategy-with-ticagrelor-on-periprocedural-myocardial-injury-in-patients-with-non-st-elevation-myocardial-infarction-undergoing-early-invasive-strategy
#35
JOURNAL ARTICLE
Orhan Furkan Karaca, Murat Cimci, Damla Raimoglou, Eser Durmaz, Hakan Yalman, Alpin Mert Tekin, Gunduz Incesu, Ferit Ulas Ozkan, Betul Yavuz, Bilgehan Karadag
Pretreatment with an oral P2Y12 receptor blocker (before coronary angiography) vs. treatment in the catheterization laboratory has been a matter of debate in patients presenting with non-ST segment elevation myocardial infarction (NSTEMI). The primary aim of this study was to assess the impact of an immediate preloading strategy with ticagrelor on periprocedural myocardial injury in patients with NSTEMI treated with an early invasive strategy. NSTEMI patients who underwent coronary angiography and subsequent percutaneous coronary intervention (PCI) within 24 hours following hospital admission were divided into two groups: the first group (pretreatment group) included patients who received ticagrelor pretreatment as soon as possible after admission, and the second group (no-pretreatment group) included patients who received a loading dose of ticagrelor after coronary angiography...
January 15, 2024: Journal of Cardiovascular Pharmacology
https://read.qxmd.com/read/38207007/nahs-reverts-chronic-stress-induced-cardiovascular-alterations-by-reducing-oxidative-stress
#36
JOURNAL ARTICLE
Jesus H Beltran-Ornelas, Diana L Silva-Velasco, Jorge Tapia-Martínez, Araceli Sánchez-López, Edgar Cano-Europa, Saúl Huerta de la Cruz, David Centurión
Chronic stress induces a group of unrecognized cardiovascular impairments, including elevated hemodynamic variables and vascular dysfunction. Moreover, hydrogen sulfide (H2S), a gasotransmitter that regulates the cardiovascular system, decreases under chronic stress. Thus, this study assessed the impact of NaHS (H2S donor) on chronic restraint stress (CRS)-induced cardiovascular changes. For that purpose, male Wistar rats were restrained for 2 h in a transparent acrylic tube over eight weeks. Then, body weight, relative adrenal gland weight, serum corticosterone, H2S-synthesizing enzymes, eNOS expression, reactive oxygen species (ROS) levels, lipid peroxidation, and reduced glutathione/oxidized glutathione (GSH2/GSSG) ratio, were determined in the thoracic aorta...
January 11, 2024: Journal of Cardiovascular Pharmacology
https://read.qxmd.com/read/38194604/identification-of-m2-macrophage-related-key-genes-in-advanced-atherosclerotic-plaques-by-network-based-analysis
#37
JOURNAL ARTICLE
Yao Yuan, Peng Wang, Haigang Zhang, Ya Liu
Atherosclerotic plaque accounts for major adverse cardiovascular events due to its vulnerability. The M1 and M2 macrophages are implicated in progression and regression of plaque, respectively. However, the therapeutic targets related M2 macrophages still remain largely elusive. In this study, CIBERSORT and WGCNA algorithms were employed to establish a weighted gene co-expression network for identifying M2 macrophage-related hub genes using GSE43292 dataset. The results shown that genes were classified into 7 modules, with the blue module (Cor = 0...
January 9, 2024: Journal of Cardiovascular Pharmacology
https://read.qxmd.com/read/38194594/the-efficacy-of-traditional-chinese-herbal-medicine-across-multiple-cardiovascular-diseases-an-umbrella-review-of-systematic-reviews-of-randomized-controlled-trials
#38
JOURNAL ARTICLE
Xi Li, Tao Yu, Qin Jiang, Jin Tan, Ke Liu
Traditional Chinese herbal medicine (CHM) has been extensively used in cardiovascular disease in modern clinical practice, alone or in combination with conventional treatment. However, its efficacy has not been assessed extensively. From inception until August 2023, we systematically searched five public literature databases to conduct the umbrella review. The inclusion criterion is systematic reviews of randomized controlled trials investigating the effect of CHM in the contemporary management of cardiovascular diseases...
January 9, 2024: Journal of Cardiovascular Pharmacology
https://read.qxmd.com/read/38180458/central-sleep-apnea-in-patients-with-coronary-heart-disease-taking-p2y12-inhibitors
#39
REVIEW
William S Tzeng, Christian F Klein, Robert H Roth, Yeilim Cho, Rohit Munagala, Heather Bonner, Sula Mazimba, Rami Khayat, William Healy, Jennifer M Lobo, Vishesh K Kapur, Younghoon Kwon
Central sleep apnea (CSA) is common in patients with heart failure. Recent studies link ticagrelor use with CSA. We aimed to evaluate CSA prevalence in patients with coronary heart disease (CHD) and whether ticagrelor use is associated with CSA. We reviewed consecutive patients with CHD who underwent a polysomnography (PSG) test over a 5-year period from 3 sleep centers. We sampled patients who were on ticagrelor or clopidogrel during a PSG test at a 1:4 ticagrelor:clopidogrel ratio. Patients with an active opioid prescription during PSG test were excluded...
January 1, 2024: Journal of Cardiovascular Pharmacology
https://read.qxmd.com/read/38180457/cardioprotective-action-of-a-novel-synthetic-19-20-edp-analog-is-sirt-dependent
#40
JOURNAL ARTICLE
Joshua W Kranrod, Ahmed M Darwesh, Wesam Bassiouni, Andy Huang, Liye Fang, Jacob V Korodimas, Adeniyi Michael Adebesin, Sailu Munnuri, John R Falck, John M Seubert
Mounting evidence suggests that cytochrome P450 epoxygenase-derived metabolites of docosahexaenoic acid, called epoxydocosapentaenoic acids (EDPs), limit mitochondrial damage after cardiac injury. In particular, the 19,20-EDP regioisomer has demonstrated potent cardioprotective action. Thus, we investigated our novel synthetic 19,20-EDP analog SA-22 for protection against cardiac ischemia-reperfusion (IR) injury. Isolated C57BL/6J mouse hearts were perfused through Langendorff apparatus for 20 minutes to obtain baseline function, followed by 30 minutes of global ischemia...
January 1, 2024: Journal of Cardiovascular Pharmacology
journal
journal
27581
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.